A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Non-Alcoholic Steatohepatitis

In brief

A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)

Key facts

Study ID: NCT04378010
Run by: Enanta Pharmaceuticals, Inc
People needed: 98
Starts: 2020-01-27
Expected to finish: 2021-11-30
Last updated by the study team: 2023-05-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Informed consent documentation signed and dated by the participant.
Male and female participants, of all ethnic origins, between the ages of 18 and 75 years, inclusive.
Participants of all ethnic origins had to have a Body Mass Index (BMI) > 25 kg/m2 and ≤ 45 except Asian participants who qualified for the study with BMI > 23 kg/m2.
Histological evidence of definite NASH based on NASH Clinical Research Network (CRN) criteria obtained from assessment of a liver biopsy by the central histopathologist. The biopsy may be obtained either 1) during the Screening window or 2) within 26 weeks prior to the Screening visit.
NAFLD Activity Score (NAS) of 4 or greater with a score of at least 1 in each component of the NAS (steatosis scored 0-3, lobular inflammation scored 0-3, ballooning scored 0-2).
Fibrosis stage 2 or 3 using the NASH CRN Histologic Scoring System.
Participants had to have Screening laboratory values for Hepatitis B surface antigen (HBsAg), anti-HCV antibodies and HCV RNA, and Human Immunodeficiency Virus (HIV) 1 and 2 antibodies (Ab) as seronegative. [Note: participants previously infected by chronic hepatitis C and treated with direct acting antivirals (DAAs) with sustained virologic response (SVR) for at least 3 years were allowed.]
A woman of childbearing potential who was sexually active with a male had to agree to use two effective methods of contraception from the date of Screening until 30 days after the last dose of study drug.
A male participant who had not had a vasectomy and was sexually active with a woman of childbearing potential had to agree to use effective contraception from the date of Screening to 90 days after the last dose of study drug.
Participant had to be willing and able to adhere to the assessments, visit schedules, prohibitions and restrictions, as described in this protocol.

You may not qualify if…

Laboratory Screening results as indicated below:
Total white blood cells (WBC) <3000 cells/mm3
Absolute neutrophil count (ANC) <1500 cells/mm3
Platelet count <140,000/mm3
International Normalized Ratio, INR >1.2 (unless due to use of anticoagulants)
Estimated glomerular filtration rate (eGFR) < 60 mL/min according to the Modification of Diet in Renal Disease (MDRD) equation
AST ≥5× ULN
ALT ≥5× ULN
ALP ≥2× ULN
Total bilirubin > 1.5 times ULN during Screening. [Note: Patients with Gilbert's syndrome were allowed following review by the Medical Monitor if they had a known history of Gilbert's syndrome with a normal direct bilirubin value and normal reticulocyte count.]
Pregnant or nursing females.
MELD: Model for End-stage Liver Disease score >12.
Clinical or laboratory evidence of known chronic liver disease such as alcoholic liver disease, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC).
History of acute liver complications due to gallstones (e.g., acute cholecystitis or acute biliary obstruction) unless the participant had a cholecytectomy (more than 3 months prior to screening).
History of liver transplant, or current placement on a liver transplant list.
Hepatorenal syndrome (type I or II).
Prior variceal hemorrhage, uncontrolled encephalopathy, liver cirrhosis Child-Pugh Class A, B, and C, esophageal varices, or refractory ascites within the previous 26 weeks of Screening and/or histological presence of liver cirrhosis.
Prior or planned ileal resection, or prior or planned bariatric surgery. [Note: Participants who had undergone gastric surgeries that did not affect drug absorption (e.g., gastric band or gastric sleeve procedures) were allowed if they were stable for at least 1 year prior to Screening. Gastrectomy or Roux-en-Y bypass was allowed if stable for at least 3 years prior to Screening.]
Participants with clinically or otherwise documented cardiovascular or cerebrovascular disease including clinically significant anomalies of rhythm or pattern of ECG, that in the judgement of the Principal Investigator (PI) could affect the safety of the participant or their ability to comply with the study requirements.
HbA1c ≥ 9.5% within 60 days prior to Day 1.
Use of a new antidiabetic regimen in the months prior to Screening including metformin, glucagon-like peptide (GLP) 1 agonists, sodium glucose cotransporter-2 (SGLT2) inhibitors, sulfonylureas, or dipeptidyl peptidase 4 (DPP4) inhibitors, insulin or peroxisome proliferator-activated receptor (PPAR)γ agonists (e.g., pioglitazone or rosiglitazone). For pre-existing antidiabetic treatment, participants were to be on a stable dose of antidiabetic drugs: (1) for at least 8 weeks (for metformin and/or sulfonylureas), (2) 12 weeks (for SGLT2 or DPP4 inhibitors), or (3) 12 weeks (for GLP-1 receptor agonists and thiazolidinediones) prior to Screening with the intention to keep the regimen stable during the study.
Use of a new statin regimen or other lipid lowering agents from 12 weeks prior to Screening.
Use of a new fibrate regimen from 12 weeks prior to Screening.
Participants with contraindications to MRI imaging, or not being able to have the MRI performed.
Participant had received any investigational agent (including investigational vaccine) or biological product within 30 days or 5 times the half-life (whichever was longer) prior to the planned first dose of study drug.

Where it is running

The Institute of Liver Health — Glendale, Arizona, United States
Dignity Health DBA St. Joseph's Hospital and Medical Center — Phoenix, Arizona, United States
Del Sol Research Management LLC — Tucson, Arizona, United States
Rajeev Krishan, MD, Inc — Bakersfield, California, United States
eStudy Site — Chula Vista, California, United States
Southern California Research Center — Coronado, California, United States
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare — Fullerton, California, United States
National Institute of Clinical Research, Inc — Garden Grove, California, United States
eStudySite - La Mesa — La Mesa, California, United States
Om Research LLC — Lancaster, California, United States
Keck Medical Center Of USC — Los Angeles, California, United States
Inland Empire Liver Foundation — Rialto, California, United States
UC Davis Medical Center — Sacramento, California, United States
Southern California Gastrointestinal and Liver Centers — San Clemente, California, United States
Precision Research Institute, Llc — San Diego, California, United States
Paradigm Clinical Research Institute — Torrance, California, United States
Universal Axon Clinical Research — Doral, Florida, United States
Fleming Island Center for Clinical Research — Fleming Island, Florida, United States
Universal Axon- Homestead, LLC — Homestead, Florida, United States
Nature Coast Clinical Research — Inverness, Florida, United States
Westside Center for Clinical Research — Jacksonville, Florida, United States
Jacksonville Center for Endoscopy - Southside ; Borland Groover Clinic — Jacksonville, Florida, United States
Encore Borland Groover Clinical Research — Jacksonville, Florida, United States
Meridien Research — Lakeland, Florida, United States
Arizona Liver Health — Chandler, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.